

***Mycobacterium tuberculosis*, Strain XTB13-111**

**Catalog No. NR-49366**

**Product Description:** *Mycobacterium tuberculosis* (*M. tuberculosis*), strain XTB13-111 was isolated in 2012 from the sputum of an HIV positive patient with tuberculosis in the Republic of Belarus. Strain XTB13-111 was deposited as resistant to ethambutol, isoniazid, rifampin and streptomycin.

**Lot<sup>1</sup>: 64064219**

**Manufacturing Date: 11MAY2016**


TEST	SPECIFICATIONS	RESULTS
<b>Phenotypic Analysis<sup>2</sup></b> Cellular morphology Colony morphology <sup>3</sup>  Growth rate Growth at 26°C Growth at 37°C Acid-fast stain Pigmentation in the dark (Scotochromogen) Photoinduction for 1 hour (Photochromogen) Nonchromogen (no pigment) Biochemical tests Niacin production <sup>4</sup> Nitrate reduction Pyrazinamidase	Gram-positive rods Report results  ≥ 7 days Negative Positive Positive (red colonies) Negative (no pigment) Negative (no pigment) Positive (no pigment)  Positive Positive Positive	Gram-positive rods Irregular, slight peaked, undulate, rough and cream (Figure 1) 21 days Negative Positive Positive (red colonies) Negative (no pigment) Negative (no pigment) Positive (no pigment)  Positive Positive Negative <sup>5</sup>
<b>Antibiotic Susceptibility Profile</b> Sensititre™ System <sup>6,7</sup> Amikacin Cycloserine Ethambutol Ethionamide Isoniazid Kanamycin Moxifloxacin Ofloxacin Para-aminosalicylic acid Rifabutin Rifampin Streptomycin	Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results	0.25 µg/mL 16 µg/mL 2 µg/mL <sup>8</sup> 1.2 µg/mL <sup>8</sup> 4 µg/mL 2.5 µg/mL 0.25 µg/mL 1 µg/mL ≤ 0.5 µg/mL <sup>8</sup> 4 µg/mL <sup>8</sup> 16 µg/mL 32 µg/mL <sup>8</sup>
<b>Genotypic Analysis</b> Sequencing of Heat Shock Protein 65 gene (~ 300 base pairs)	≥ 99% sequence identity to <i>M. tuberculosis</i> , strain XTB13-111 (GenBank: JLLM01000002.1)	99.7% sequence identity to <i>M. tuberculosis</i> , strain XTB13-111 (GenBank: JLLM01000002.1) <sup>9</sup>
<b>Purity (post-freeze)</b> Middlebrook 7H10 agar with OADC enrichment <sup>10</sup>  Tryptic Soy agar <sup>11</sup>	Growth consistent with expected colony morphology Report results	Growth consistent with expected colony morphology No growth
<b>Viability (post-freeze)<sup>3</sup></b>	Growth	Growth

<sup>1</sup>NR-49366 was produced by inoculation of the deposited material into Middlebrook 7H9 broth with ADC enrichment. Broth inoculum was added to Middlebrook 7H10 agar with OADC enrichment kolles, which were grown for 62 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> to produce this lot.

<sup>2</sup>Information on Mycobacterium testing is available from Ribón, W. "Biochemical Isolation and Identification of Mycobacteria." [Biochemical Testing](#).

- (2012) Jose C. Jimenez-Lopez (Ed.), InTech, <http://www.intechopen.com/books/biochemical-testing/biochemical-isolation-and-identification-of-mycobacteria> and Lévy-Frébault, V. V. and F. Portaels. "Proposed Minimal Standards for the Genus *Mycobacterium* and for Description of New Slowly Growing *Mycobacterium* Species." *Int. J. Syst. Bacteriol.* 42 (1992): 315-323. PubMed: 1581193.
- <sup>3</sup>21 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Middlebrook 7H10 agar with OADC enrichment
- <sup>4</sup>All mycobacteria produce niacin but only *M. tuberculosis* accumulates it, resulting in a positive test for *M. tuberculosis*.
- <sup>5</sup>A negative result may indicate a low expression of pyrazinamidase activity or a mutation to the pyrazinamidase/nicotinamidase (*pncA*) gene conferring resistance to pyrazinamidase (Sheen, P., et al. "Effect of Pyrazinamidase Activity on Pyrazinamide Resistance in *Mycobacterium tuberculosis*." *Tuberculosis (Edinb)*. 89 (2009): 109-113. PubMed: 19249243.).
- <sup>6</sup>Sensititre™ System *Mycobacterium tuberculosis* MIC Plate, Thermo Scientific™, catalog number MYCOTB
- <sup>7</sup>Minimum Inhibitory Concentration (MIC); No Clinical & Laboratory Standards Institute (CLSI) interpretations of the Sensititre™ System data for *M. tuberculosis* are currently available.
- <sup>8</sup>For streptomycin, ethionamide, para-aminosalicylic acid, rifabutin and ethambutol, the endpoint for these drugs is determined by the well with approximately 80% inhibition of growth compared to the positive control well with no drug.
- <sup>9</sup>Also consistent with *M. africanum*, *M. bovis*, *M. canettii*, *M. caprae* and *M. microti*
- <sup>10</sup>Purity of this lot was assessed for 93 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.
- <sup>11</sup>Purity of this lot was assessed for 21 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.

Figure 1: Colony Morphology



Date: 25 OCT 2017

Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

